VIVUS to Present at Two Upcoming Investor Conferences

Thursday, March 4, 2010 Press Release J E 4
MOUNTAIN VIEW, Calif., March 3 VIVUS, Inc.(Nasdaq: VVUS) today announced that Timothy Morris, Chief Financial Officer,will present an overview of the company at two investment conferences duringthe month of March.

A live audio webcast and 30-day archive of the presentations will beavailable on VIVUS' website at


VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetesand sexual health. The company's lead product in clinical development,Qnexa(R), has completed phase 3 clinical trials for the treatment of obesityand an NDA has been filed and accepted by the FDA, with an action date ofOctober 28, 2010. Qnexa is also in phase 2 clinical development for thetreatment of type 2 diabetes and obstructive sleep apnea. In the area ofsexual health, VIVUS is in phase 3 development with avanafil, a potentiallybest-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and inphase 2 development of Luramist(TM) for the treatment of hypoactive sexualdesire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generationtherapy for the treatment of ED, is already on the market and generatingrevenue for VIVUS. For more information about the company, please conference presentation schedule is as follows: Cowen and Company 30th Annual Health Care Conference March 10, 2010 at 9:30 a.m. ET The Boston Marriott Copley Place, Boston, MA Roth Capital Partners 22nd Annual OC Growth Stock Conference March 16, 2010 at 12:00 p.m. PT The Ritz Carlton, Dana Point, CA



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
PDI to Present at the ROTH Capital Partners 22nd A...
Gynecologic Oncology Group (GOG) Notifies CTI That...